SciClone Pharmaceuticals Inc. (NASDAQ:SCLN)’s share price traded down 3.2% during trading on Thursday . The stock traded as low as $10.31 and last traded at $10.36, with a volume of 264,129 shares traded. The stock had previously closed at $10.70.

The company has a 50-day moving average of $12.27 and a 200-day moving average of $11.38. The firm has a market cap of $515.56 million and a PE ratio of 19.13.

SciClone Pharmaceuticals (NASDAQ:SCLN) last released its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported $0.19 EPS for the quarter. The business had revenue of $36.50 million for the quarter, compared to analyst estimates of $33.60 million. On average, analysts anticipate that SciClone Pharmaceuticals Inc. will post $0.33 EPS for the current fiscal year.

A hedge fund recently bought a new stake in SciClone Pharmaceuticals stock. Matarin Capital Management LLC purchased a new stake in shares of SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 173,899 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,600,000. Matarin Capital Management LLC owned 0.35% of SciClone Pharmaceuticals at the end of the most recent reporting period.

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.